FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037274145> ?p ?o ?g. }

• W2037274145 endingPage "829" @default.
• W2037274145 startingPage "821" @default.
• W2037274145 abstract "Women who have had breast cancer may be at higher risk for osteoporosis than other women. First, they are more likely to undergo early menopause, due to chemotherapy-induced ovarian failure or oopherectomy. In addition, chemotherapy may have a direct adverse effect on bone mineral density (BMD), and osteoclastic activity may increase from the breast cancer itself. While estrogen therapy is considered standard for the prevention and treatment of osteoporosis, use of estrogen in women with a history of breast cancer is usually contraindicated. The approach to osteoporosis in women with breast cancer is also affected by the use of tamoxifen in many, as this drug appears to have opposite effects on BMD in premenopausal and postmenopausal women. We have reviewed therapeutic alternatives for the prevention and treatment of osteoporosis, focusing on patients with a history of breast cancer. Alendronate and raloxifene are currently approved in the United States for the prevention of osteoporosis; alendronate, raloxifene, and calcitonin are approved for treatment. Alendronate has the greatest positive effect on BMD and reduces the incidence of vertebral and nonvertebral fractures. Raloxifene and calcitonin appear to reduce the incidence of vertebral fractures; their effects on the incidence of nonvertebral fractures are not yet proven. Although no published studies specifically address the use of these approved agents for osteoporosis in women with breast cancer, understanding their relative effects on BMD in postmenopausal women in general will facilitate therapy selection in this population. Postmenopausal women with a history of breast cancer should undergo bone mineral analysis. Normal results and absence of other risk factors ensure that calcium and vitamin D intake are adequate. If osteopenia or other risk factors are present, preventive therapy with alendronate or raloxifene should be considered. For osteoporosis, treatment with alendronate should be strongly considered. Raloxifene and calcitonin are alternatives when alendronate is contraindicated. Further studies are needed to evaluate the optimal timing of initial bone mineral analysis in premenopausal women after breast cancer diagnosis and to determine the value of preventive treatment in women scheduled to undergo chemotherapy." @default.
• W2037274145 created "2016-06-24" @default.
• W2037274145 creator A5037929298 @default.
• W2037274145 creator A5065306642 @default.
• W2037274145 creator A5091500961 @default.
• W2037274145 date "2000-08-01" @default.
• W2037274145 modified "2023-10-02" @default.
• W2037274145 title "Prevention and Treatment of Osteoporosis in Women With Breast Cancer" @default.
• W2037274145 cites W1800396987 @default.
• W2037274145 cites W1968485252 @default.
• W2037274145 cites W1971782371 @default.
• W2037274145 cites W1972391190 @default.
• W2037274145 cites W1979353935 @default.
• W2037274145 cites W1981476886 @default.
• W2037274145 cites W1983364263 @default.
• W2037274145 cites W1989622431 @default.
• W2037274145 cites W1995999743 @default.
• W2037274145 cites W1997883187 @default.
• W2037274145 cites W2006021879 @default.
• W2037274145 cites W2006861025 @default.
• W2037274145 cites W2017707906 @default.
• W2037274145 cites W2020564919 @default.
• W2037274145 cites W2034238658 @default.
• W2037274145 cites W2034606501 @default.
• W2037274145 cites W2040573139 @default.
• W2037274145 cites W2040874005 @default.
• W2037274145 cites W2041705502 @default.
• W2037274145 cites W2047543524 @default.
• W2037274145 cites W2050478114 @default.
• W2037274145 cites W2051399396 @default.
• W2037274145 cites W2070632695 @default.
• W2037274145 cites W2070702992 @default.
• W2037274145 cites W2074791841 @default.
• W2037274145 cites W2089331118 @default.
• W2037274145 cites W2093076324 @default.
• W2037274145 cites W2099116126 @default.
• W2037274145 cites W2106632157 @default.
• W2037274145 cites W2112629831 @default.
• W2037274145 cites W2114358979 @default.
• W2037274145 cites W2123927174 @default.
• W2037274145 cites W2127677509 @default.
• W2037274145 cites W2130251213 @default.
• W2037274145 cites W2141647078 @default.
• W2037274145 cites W2153009489 @default.
• W2037274145 cites W2159858973 @default.
• W2037274145 cites W2161837912 @default.
• W2037274145 cites W2255137252 @default.
• W2037274145 cites W2313507666 @default.
• W2037274145 cites W2314110838 @default.
• W2037274145 cites W2315905420 @default.
• W2037274145 cites W2321227665 @default.
• W2037274145 cites W2329927106 @default.
• W2037274145 cites W2337977161 @default.
• W2037274145 cites W2340685677 @default.
• W2037274145 cites W2413832721 @default.
• W2037274145 cites W4245166850 @default.
• W2037274145 cites W4301519319 @default.
• W2037274145 doi "https://doi.org/10.4065/75.8.821" @default.
• W2037274145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10943237" @default.
• W2037274145 hasPublicationYear "2000" @default.
• W2037274145 type Work @default.
• W2037274145 sameAs 2037274145 @default.
• W2037274145 citedByCount "42" @default.
• W2037274145 countsByYear W20372741452012 @default.
• W2037274145 countsByYear W20372741452014 @default.
• W2037274145 countsByYear W20372741452018 @default.
• W2037274145 countsByYear W20372741452022 @default.
• W2037274145 countsByYear W20372741452023 @default.
• W2037274145 crossrefType "journal-article" @default.
• W2037274145 hasAuthorship W2037274145A5037929298 @default.
• W2037274145 hasAuthorship W2037274145A5065306642 @default.
• W2037274145 hasAuthorship W2037274145A5091500961 @default.
• W2037274145 hasBestOaLocation W20372741451 @default.
• W2037274145 hasConcept C120665830 @default.
• W2037274145 hasConcept C121332964 @default.
• W2037274145 hasConcept C121608353 @default.
• W2037274145 hasConcept C126322002 @default.
• W2037274145 hasConcept C143998085 @default.
• W2037274145 hasConcept C2776541429 @default.
• W2037274145 hasConcept C2776886416 @default.
• W2037274145 hasConcept C2777176818 @default.
• W2037274145 hasConcept C2778562196 @default.
• W2037274145 hasConcept C2779889926 @default.
• W2037274145 hasConcept C2908647359 @default.
• W2037274145 hasConcept C29456083 @default.
• W2037274145 hasConcept C530470458 @default.
• W2037274145 hasConcept C61511704 @default.
• W2037274145 hasConcept C71924100 @default.
• W2037274145 hasConcept C99454951 @default.
• W2037274145 hasConceptScore W2037274145C120665830 @default.
• W2037274145 hasConceptScore W2037274145C121332964 @default.
• W2037274145 hasConceptScore W2037274145C121608353 @default.
• W2037274145 hasConceptScore W2037274145C126322002 @default.
• W2037274145 hasConceptScore W2037274145C143998085 @default.
• W2037274145 hasConceptScore W2037274145C2776541429 @default.
• W2037274145 hasConceptScore W2037274145C2776886416 @default.
• W2037274145 hasConceptScore W2037274145C2777176818 @default.
• W2037274145 hasConceptScore W2037274145C2778562196 @default.

• next